Prodotti
Efficacy and safety of polydimethylsiloxane injection (Macroplastique®) for the treatment of female stress urinary incontinence: results of a series of 85 patients with ≥3 years of follow-up
2020 - Maurizio Serati , Marco Soligo , Andrea Braga , Simona Cantaluppi, Anna C. Coluccia, Maria C. Di Dedda, Stefano Salvatore , Irene Cetin , Fabio Ghezzi

To assess the long-term efficacy and safety of polydimethylsiloxane injection (Macroplastique", Cogentix Medical, Orangeburg, New York, USA) for the treatment of female stress urinary incontinence (SUI), with a minimum follow-up of 3 years
This is an observational analytical prospective cohort study conducted in a single uro-gynaecological unit. All consecutive women with urodynamically confirmed pure SUI treated with the Macroplastique procedure, were included. Data regarding patient outcomes (International Consultation on Incontinence Questionnaire–Short Form, Patient Global Impression of Improvement, and patient satisfaction scores), objective cure rates, and adverse events were collected during follow-up.

BJU International · September 2018. DOI: 10.1111/bju.14550

Trattamento con Macroplastique: 2 anni di Follow up
2010 - Ghoniem, G., Corcos, J., Comiter, C., Westney, O.L., & Herschorn, S

Durability of urethral bulking agent injecton for female stress urinary incontinence: 2-year multicenter study result.
We evaluated the durability of the urethral bulking agent Macroplastique® for stress urinary incontinence in a 24-month study in women with a previously documented successful outcome 12 months after the last injection.

J Urol, 183, 1444-1449.